Pivekimab
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC) . Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) [1][2].
Product Specifications
CAS Number
2234335-84-1
UNSPSC
12352203
Target
ADC Antibody; Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pivekimab.html
Purity
97.19
Solubility
10 mM in DMSO
Smiles
[Pivekimab]
Molecular Weight
(145.98 kDa)
References & Citations
[1]Patrick ZM, et, al. Methods of treatment using anti-CD123 immunoconjugates. WO2020092533.|[2]Poussard, et al. Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model. Blood 142 (2023) : 2791.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RDSM126 100 Assays
Granule Bound Starch Synthase Microplate Assay Kit
Sign In for Pricing
View Details 
HA751136 100 µL
Histone H3 (mono methyl K4) Recombinant Rabbit monoclonal Antibody
Sign In for Pricing
View Details 
TP310368 20 µg
Myostatin Propeptide (MSTN) (NM_005259) Human Recombinant Protein
Sign In for Pricing
View Details 
